RXRX
Recursion Pharmaceuticals-a
$7.47
Earnings Summary
Revenue | $10.89Mn |
Net Profits | $-93Mn |
Net Profit Margins | -853.88% |
Highlights
Recursion Pharmaceuticals-a’s revenue fell -20.36% since last year same period to $10.89Mn in the Q4 2023. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 7.81% jump in its revenue since last 3-months.
Recursion Pharmaceuticals-a’s net profit fell -61.79% since last year same period to $-93Mn in the Q4 2023. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 0.02% jump in its net profits since last 3-months.
Recursion Pharmaceuticals-a’s net profit margin fell -103.16% since last year same period to -853.88% in the Q4 2023. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 7.27% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Recursion Pharmaceuticals-a post its latest quarter earnings
EPS Estimate Current Quarter | -0.42 |
EPS Estimate Current Year | -0.42 |
Highlights
Recursion Pharmaceuticals-a’s earning per share (EPS) estimates for the current quarter stand at -0.42 - a 6.67% jump from last quarter’s estimates.
Recursion Pharmaceuticals-a’s earning per share (EPS) estimates for the current year stand at -0.42.
Key Ratios
Key ratios of the Recursion Pharmaceuticals-a post its Q4 2023 earnings
Earning Per Share (EPS) | -0.42 |
Highlights
Recursion Pharmaceuticals-a’s earning per share (EPS) fell -35.48% since last year same period to -0.42 in the Q4 2023. This indicates that the Recursion Pharmaceuticals-a has generated -35.48% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2023-08-08 | -0.37 | -0.38 | -2.7% |
2024-02-29 | -0.45 | -0.42 | 6.67% |
2023-11-09 | -0.38 | -0.43 | -13.16% |
2023-05-08 | -0.35 | -0.34 | 2.86% |
₹0 US Stocks a/c Opening Fee